| Literature DB >> 22606052 |
Izabela Korona-Glowniak1, Ewelina Grywalska, Beata Chudzik, Agnieszka Bojarska-Junak, Anna Malm, Jacek Rolinski.
Abstract
The aim of the study was to assess the frequency and predisposing factors of colonization of upper respiratory tract by Gram-negative rods (GNRs) in chronic lymphocytic leukemia (CLL) patients. Antimicrobial susceptibility of the isolated strains was determined. A significantly higher frequency of GNR colonization in CLL patients was observed (36.7%) in comparison to healthy volunteers (8.3%). GNR isolates mainly belonged to the Enterobacteriaceae family. Three isolates of GNR demonstrating presence of AmpC β-lactamases and one ESBL-producing strain were obtained from CLL patients. GNR colonization rate was higher among CLL patients with lower level of IgG in serum (P = 0.017), with higher number of neutrophils (P = 0.039) or higher number of lymphocytes in serum (P = 0.053). The longer the time elapsed since diagnosis, the higher the frequency of GNR colonization observed. Multivariate analysis showed importance of the Rai stage, number, and type of infections as independent predictors of GNR colonization in CLL patients.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22606052 PMCID: PMC3346184 DOI: 10.1100/2012/617218
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Selected demographic, clinical, and laboratory parameters of the CLL patients.
| Parameter | No. of patients (%) | Mean ± SD | Range |
|---|---|---|---|
| Age | 60.47 ± 8.3 | 43–80 | |
| Gender: | |||
| Males | 12 (40) | ||
| Females | 18 (60) | ||
| The Rai stage: | |||
| 0 | 8 (26.7) | ||
| 1 | 8 (26.7) | ||
| 2 | 11 (36.7) | ||
| 3 | 3 (10.0) | ||
| Period from diagnosis (years) | 5.0 ± 3.3 | 0–11 | |
| No. of infections per year | 4.4 ± 3.1 | 1–11 | |
| Type of infection: | |||
| URTIs | 12 (40.0) | ||
| LRTIs | 5 (16.7) | ||
| URTs+LRTIs | 6 (20.0) | ||
| LTRIs+skin infections | 1 (3.3) | ||
| URTIs+LRTIs+skin infections | 2 (6.7) | ||
| Lymphocytes (%) | 72.1 ± 11.8 | 48.3–89.3 | |
| Lymphocytes (103/mm3) | 27.2 ± 23.3 | 5.3–90.9 | |
| Neutrophils (%) | 22.1 ± 17.4 | 3.5–91.0 | |
| Neutrophils (103/mm3) | 6.1 ± 4.9 | 1.2–20.5 | |
| IgA (mg/dL) | 153.0 ± 103.2 | 3–380 | |
| IgG (mg/dL) | 774.3 ± 303.1 | 320–1616 | |
| IgM (mg/dL) | 64.3 ± 52.8 | 4–220 | |
| CD3+ cells (%) | 13.8 ± 11.9 | 1.2–56.2 | |
| CD19+ cells (%) | 80.6 ± 13.5 | 35.2–96.8 | |
| CD5+CD19+ cells (%) | 74.6 ± 20.2 | 45–96.7 | |
| CD19+ZAP70+ cells (%) | 16.2 ± 13.1 | 1.7–45.3 | |
| Negative | 21 (75.0) | ||
| Positive | 7 (25.0) | ||
| CD19+CD38+ cells (%) | 17.7 ± 18.7 | 0.3–56.7 | |
| Negative | 20 (71.4) | ||
| Positive | 8 (28.6) | ||
| ZAP70 expression in relation to CD38 expression on B lymphocytes | |||
| ZAP70 (−), CD38 (−) | 18 (64.3) | ||
| ZAP70 (+), CD38 (+) | 5 (17.9) | ||
| ZAP70 (+), CD38 (−) | 2 (7.1) | ||
| ZAP70 (−), CD38 (+) | 3 (10.7) | ||
| CD19+CD25+ cells (%) | 39.0 ± 25.5 | 1.9–89.8 | |
| Negative | 7 (25.0) | ||
| Positive | 21(75.0) | ||
| CD19+CD69+ cells (%) | 23.4 ± 18.3 | 0.4–60.8 | |
| CD3+CD25+ cells (%) | 20.5 ± 12.5 | 2.4–52.8 | |
| CD3+CD69+ cells (%) | 6.2 ± 7.3 | 0.5–29.3 | |
| CD3+CD4+cells (%) | 7.5 ± 6.4 | 0.8–33.1 | |
| CD3+CD8+cells (%) | 7.0 ± 6.1 | 0.5–24.2 | |
| CD4+ to CD8+ cells ratio | 1.4 ± 0.7 | 0.3–3.2 | |
| CD4+CD8+cells (%) | 0.5 ± 0.7 | 0.03–3.6 |
URTIs: upper respiratory tract infections, LRTIs: lower respiratory tract infections.
Gram-negative rods isolated from upper respiratory tract from examined patients and their resistance patterns.
| Species | No. of isolates | Resistance pattern (no. of isolates) |
|---|---|---|
|
| 4 | S (4) |
|
| 2 | S (1); Am (1) |
|
| 2 | Am Pip Tic Tob (1); Am Pip Tic (1) |
|
| 1 | Am Amc Pip Tzp Tic Tim Cxm Ctx Caz Te |
|
| 1 | Am Amc Pip Tzp Tic Tim Cxm Ctx Caz Fep Atm Ipm Te Sxt |
|
| 1 | Cxm |
|
| 1 | Am Amc Pip Tzp Tic Tim Cxm Ctx Caz |
|
| 1 | Am Amc Pip Tzp Tic Tim Cxm Ctx Caz |
|
| 1 | Amc Te Sxt |
Am, ampicillin; Amc, amoxycillin/clavulanate acid; Pip, piperacillin; Tzp, piperacillin/tazobactam; Tic, ticarcillin; Tim, ticarcillin/clavulanate acid; Cxm, cefuroxime; Ctx, cefotaxime; Caz, ceftazidime; Fep, cefepime; Atm, aztreonam; Ipm, imipenem; Te, tetracycline; Sxt, trimetoprim/sulfamethoxazole.
The association between Gram-negative rods colonization and selected demographic, clinical or laboratory parameters in CLL patients.
| Predictors | No. of patients or mean ± SD |
| |
|---|---|---|---|
| GNR colonized ( | Noncolonized ( | ||
| Age | 58.2 ± 6.3 | 59.9 ± 9.8 | 0.73 |
| Males | 2 (18.2) | 10 (52.6) | 0.12; 1.7 (1.0–3.0) |
| Rai stage: | 0.03* | ||
| 0 | 1 (9.1) | 7 (36.8) | |
| 1 | 1 (9.1) | 7 (36.8) | |
| 2 | 7 (63.6) | 4 (21.1) | |
| 3 | 2 (18.2) | 1 (5.3) | |
| Period from diagnosis (years) | 6.8 ± 2.1 | 3.9 ± 3.3 | 0.025* |
| No. of infections per year | 3.9 ± 1.9 | 3.6 ± 2.2 | 0.26 |
| Types of infections | 0.22 | ||
| Lymphocytes (%) | 71.1 ± 11.9 | 71.6 ± 11.6 | 0.83 |
| Lymphocytes (103/mm3) | 39.2 ± 23.5 | 16.4 ± 9.0 | 0.053 |
| Neutrophils (%) | 20.0 ± 11.7 | 19.9 ± 11.3 | 0.85 |
| Neutrophils (103/mm3) | 7.5 ± 4.0 | 5.3 ± 5.3 | 0.039* |
| IgA (mg/dL) | 90.3 ± 45.3 | 146.4 ± 100.2 | 0.21 |
| IgG (mg/dL) | 563.3 ± 217.5 | 940.0 ± 307.5 | 0.017* |
| IgM (mg/dL) | 31.5 ± 14.8 | 62.1 ± 50.6 | 0.95 |
| CD3+ cells (%) | 13.4 ± 5.3 | 11.7 ± 7.9 | 0.86 |
| CD19+ cells (%) | 80.5 ± 7.4 | 84.1 ± 8.9 | 0.60 |
| CD5+CD19+ cells (%) | 18.9 ± 8.8 | 72.5 ± 24.6 | 0.55 |
| CD19+ZAP70+ cells (%) | 14.5 ± 14.5 | 18.3 ± 14.1 | 0.77 |
| Positive/negative | 3/4 (42.9) | 7/14 (33.3) | 0.67; 1.5 (0.3–1.6) |
| CD19+CD38+ cells (%) | 21.3 ± 17.1 | 18.2 ± 19.1 | 0.38 |
| Positive/negative | 4/4 (50.0) | 6/14 (30.0) | 0.40; 2.3 (0.4–12.6) |
| CD19+CD25+ cells (%) | 26.2 ± 23.4 | 44.2 ± 27.1 | 0.14 |
| Positive/negative | 8/13 (38.1) | 2/5 (28.6) | 1.0; 1.5 (0.2–9.9) |
| CD19+CD69+ cells (%) | 16.0 ± 13.1 | 21.6 ± 20.7 | 0.88 |
| CD3+CD25+ cells (%) | 18.9 ± 8.8 | 18.5 ± 8.3 | 0.72 |
| CD3+CD69+ cells (%) | 2.6 ± 1.3 | 7.6 ± 7.9 | 0.55 |
| CD3+CD4+cells (%) | 8.3 ± 3.2 | 6.1 ± 3.3 | 0.19 |
| CD3+CD8+cells (%) | 7.3 ± 4.1 | 7.3 ± 6.1 | 0.98 |
| CD4+-to-CD8+ cells ratio | 1.3 ± 0.7 | 1.3 ± 0.8 | 0.95 |
| CD4+CD8+cells (%) | 0.4 ± 0.1 | 0.4 ± 0.4 | 1.0 |
*P < 0.05.
Logistic regression analysis of factors predictive of GNR colonization in CLL patients.
| Predictors | OR (95%CI) |
|
|---|---|---|
| Rai stage | 8.1 (1.4–47.6) | 0.014 |
| No. of infections per year | 4.2 (1.1–15.8) | 0.027 |
| Types of infections | 0.06 (0.005–0.7) | 0.018 |